Brooklyn Investment Group Grows Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Brooklyn Investment Group grew its stake in Illumina, Inc. (NASDAQ:ILMN) by 20.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 611 shares of the life sciences company’s stock after purchasing an additional 104 shares during the period. Brooklyn Investment Group’s holdings in Illumina were worth $82,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Empowered Funds LLC grew its holdings in Illumina by 1.7% in the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock valued at $516,000 after buying an additional 66 shares in the last quarter. Caprock Group LLC increased its position in Illumina by 3.0% during the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after purchasing an additional 83 shares during the last quarter. Integrated Advisors Network LLC raised its stake in Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares during the period. Moors & Cabot Inc. boosted its holdings in Illumina by 1.7% in the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock valued at $759,000 after purchasing an additional 95 shares during the last quarter. Finally, Carson Advisory Inc. grew its stake in shares of Illumina by 3.8% in the 3rd quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock valued at $360,000 after buying an additional 102 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Down 0.5 %

Shares of Illumina stock opened at $136.67 on Monday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The company has a market capitalization of $21.68 billion, a P/E ratio of -13.72 and a beta of 1.11. The company has a 50 day moving average of $139.60 and a 200 day moving average of $133.57.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the previous year, the firm posted $0.33 earnings per share. The company’s revenue was down 3.5% compared to the same quarter last year. As a group, research analysts forecast that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ILMN. Stephens upped their price objective on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. JPMorgan Chase & Co. upped their price target on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Leerink Partners raised their price objective on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and decreased their target price for the company from $190.00 to $165.00 in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada lifted their price target on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Eight investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.